| Literature DB >> 34071878 |
Sue E Crawford1, Sasirekha Ramani1, Sarah E Blutt1, Mary K Estes1,2.
Abstract
Historically, knowledge of human host-enteric pathogen interactions has been elucidated from studies using cancer cells, animal models, clinical data, and occasionally, controlled human infection models. Although much has been learned from these studies, an understanding of the complex interactions between human viruses and the human intestinal epithelium was initially limited by the lack of nontransformed culture systems, which recapitulate the relevant heterogenous cell types that comprise the intestinal villus epithelium. New investigations using multicellular, physiologically active, organotypic cultures produced from intestinal stem cells isolated from biopsies or surgical specimens provide an exciting new avenue for understanding human specific pathogens and revealing previously unknown host-microbe interactions that affect replication and outcomes of human infections. Here, we summarize recent biologic discoveries using human intestinal organoids and human enteric viral pathogens.Entities:
Keywords: Transwell®; diarrhea; enteric virus; enteroid; gastrointestinal infection; host–virus interactions; human intestinal organoid
Mesh:
Year: 2021 PMID: 34071878 PMCID: PMC8230193 DOI: 10.3390/v13060999
Source DB: PubMed Journal: Viruses ISSN: 1999-4915 Impact factor: 5.048
Figure 1Human intestinal organoids. (a) Generation of HIOs from stem cells isolated from intestinal biopsies or tissue. (b) HIOs can be cultured as 3D HIOs in extracellular matrices such as Matrigel® or plated, either as 2D cultures on 96 well plates or as polarized monolayers on Transwells®. HIOs can be plated on either on Matrigel®- or collagen-coated surfaces. In each of these formats, HIOs can be used as undifferentiated or differentiated 3D or 2D cultures. The apical and basolateral surfaces can be accessed by pathogens on Transwells®, while the apical surface of 3D HIOs is accessed by mechanical disruption. Created with BioRender.com (accessed on 26 May 2021).
Viral tropism, route of infection/release and interferon response to infection in HIOs.
| Virus | Supports Virus Replication | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Previously | Undifferentiated/ | Differentiated | Susceptible Cell Type(s) | Route of Infection | Route of Release | IFN Response | Replication | References | ||
| Human Rotavirus | No | Poorly | D, J, I, C $ | Enterocyte, Enteroendocrine | Baolateral > Apical | NT | Type III | [ | ||
| Human Norovirus | Yes | No | D, J, I, not C | Enterocyte, Enteroendocrine | Apical ** | NT | Type III | neutralized by monoclonal antibodies | [ | |
| Human Astrovirus | Some strains | D, J, I, C # | D, J ** | Progenitor, Enterocyte, Goblet | Apical ** | NT | Type I and Type III | inhibited by heat, 2CMC *; increased by ruxolitinib *** | [ | |
| Human Adenoviruses | Enteric | No | I ** | I ** | Enterocyte | Apical ** | NT | |||
| Respiratory | No | I ** | I ** | Goblet | Apical ** | NT | neutralized by enteric α-defensin HD5 | [ | ||
| Enteroviruses | Enterovirus 11 | No | NT | Fetal ** | Enterocyte, Enteroendocrine | Basolateral | Both but > Basolateral | Type III | increased by ruxolitinib | [ |
| Enterovirus 71 | No | NT | Fetal ** | Goblet | Apical | Apical | Type III | |||
| SARS-CoV-2 | No | Yes | D, I, C | Enterocyte | Apical 1000 fold > basolateral | NT | Type III | inhibited by imatinib, mycophenolic acid, quinacrine dihydrochloride ## | [ | |
$ D (duodenum), J (jejunum), I (ileum), C (colon). # segments from adult and fetal patient donors. * Ribavirin and 2′-C-methylcytidine (2CMC), nucleoside analogues. ** only tested. *** ruxolitinib, an ATP mimetic janus-associated kinases. (JAKs) inhibitor that blocks STAT1 activation and inhibits ISG induction. ## imatinib, tyrosine kinase receptor inhibitor; mycophenolic acid, immunosuppressant, inhibitor of inosine monophosphate dehydrogenase; quinacrine dihydrochloride, suppresses NF-KB, activates p53 signaling and apoptosis. NT—Not tested.
Figure 2Expression of genes involved in innate immunity and immune modulation following infection of differentiated human intestinal organoids with SARS-CoV-2 coronavirus. Genes are listed on the left, and infection conditions are listed at the top. From [34].
Figure 3Overview of what we have learned from virus–HIO studies. Future areas of research are listed in green. Created with BioRender.com (accessed on 26 May 2021).
Current questions for HIO–enteric virus research.
| Can epithelial cell responses to virus infection help explain pathogenesis? |
| Do goblet, enteroendocrine, or tuft cells have unique antiviral innate pathways to limit virus infection and/or replication? |
| Can novel viral receptor(s) be identified using polarized HIO monolayers in the transwell system? |
| Can viral interference, or bacterial–viral, and parasite–viral interactions, be modeled in HIOs? |
| Do all viruses use the same mechanisms to cross the intestinal epithelial barrier for systemic dissemination? |
| Can unique aspects of enteric virus replication, including dissecting slow viral kinetics, be elucidated in HIOs? |
| Will cell tropism for infection or epithelial cell responses differ in more advanced HIO cultures containing immune cells, innervation, or mesenchyme? |